You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Albumin-Bound Paclitaxel

Showing 1 - 25 of 4,668
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

PDAC - Pancreatic Ductal Adenocarcinoma Trial (Combination of sitagliptin+ gemcitabine + nab-paclitaxel)

Not yet recruiting
  • PDAC - Pancreatic Ductal Adenocarcinoma
  • Combination of sitagliptin+ gemcitabine + nab-paclitaxel
  • (no location specified)
Jul 9, 2023

Advanced Non-squamous Non-small-cell Lung Cancer, Recurrent Non-Squamous NSCLC, Metastatic Non-squamous Non Small Cell Lung

Not yet recruiting
  • Advanced Non-squamous Non-small-cell Lung Cancer
  • +2 more
  • Beijing, Beijing, China
    Peking University First Hospital Ethics Committee
Sep 10, 2023

Breast Cancer Trial in Chengdu (Pyrotinib combined with albumin-bound paclitaxel and trastuzumab)

Recruiting
  • Breast Cancer
  • Pyrotinib combined with albumin-bound paclitaxel and trastuzumab
  • Chengdu, Chengdu, Sichuan, China, China
    West China Hospital, Sichuan University
Oct 7, 2022

Locally Advanced Pancreatic Cancer Trial in Shanghai (Tumor treating fields combined with Gemcitabine HCl and albumin binding

Not yet recruiting
  • Locally Advanced Pancreatic Cancer
  • Tumor treating fields combined with Gemcitabine hydrochloride and albumin binding paclitaxel
  • Gemcitabine hydrochloride and albumin binding paclitaxel
  • Shanghai, Shanghai, China
    Huashan Hospital Affiliated to Fudan University
Dec 8, 2022

Ovarian Carcinoma, Platinum-resistant Ovarian Cancer, Recurrent Ovarian Carcinoma Trial in Beijing (Albumin-bound paclitaxel and

Recruiting
  • Ovarian Carcinoma
  • +6 more
  • Albumin-bound paclitaxel and bevacizumab
  • Beijing, Beijing, China
    Lei Li
Mar 26, 2022

Gastric Cancer, GastroEsophageal Cancer Trial in Wuhan (Albumin-bound Paclitaxel Plus SHR-1210 (PD-1 inhibitor), Albumin-bound

Active, not recruiting
  • Gastric Cancer
  • GastroEsophageal Cancer
  • Albumin-bound Paclitaxel Plus SHR-1210 (PD-1 inhibitor)
  • Albumin-bound Paclitaxel
  • Wuhan, Hubei, China
    Tongji hospital of Tongji Medical College, Huazhong University o
Jan 21, 2023

Recurrent Cervical Cancer Trial in Guangzhou (anti-PD-1+Albumin-Bound Paclitaxel)

Active, not recruiting
  • Recurrent Cervical Cancer
  • anti-PD-1+Albumin-Bound Paclitaxel
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
May 26, 2022

Early Breast Cancer Trial in Zhengzhou (monosialic gangliosides, Placebo)

Withdrawn
  • Early Breast Cancer
  • monosialic gangliosides
  • Placebo
  • Zhengzhou, Henan, China
    Henan Cancer Hospital
Nov 19, 2022

Breast Cancer Trial in Beijing (doxorubicin, epirubicin, pirarubicin)

Not yet recruiting
  • Breast Cancer
  • Beijing, Beijing, China
    Cancer Hospital, ChineseAMS
Mar 17, 2022

Angiosarcoma Metastatic Trial in Guangzhou (Abraxane combined with liposomal doxorubicin)

Recruiting
  • Angiosarcoma Metastatic
  • Abraxane combined with liposomal doxorubicin
  • Guangzhou, Guangdong, China
    Xing Zhang
Sep 4, 2022

Pancreatic Cancer Trial in Tianjin (surufatinib + gemcitabine + nab-paclitaxel)

Recruiting
  • Pancreatic Cancer
  • surufatinib + gemcitabine + nab-paclitaxel
  • Tianjin, Tianjin, China
    Tianjin Medical University Cancer Institute and Hospital
Jun 15, 2023

Ovarian Cancer Trial (albumin-bound paclitaxel, paclitaxel)

Not yet recruiting
  • Ovarian Cancer
  • (no location specified)
Mar 31, 2022

Advanced Gastric Adenocarcinoma Trial in Ho-nan (Camrelizumab, Albumin-bound paclitaxel, S-1)

Recruiting
  • Advanced Gastric Adenocarcinoma
  • Camrelizumab, Albumin-bound paclitaxel, S-1
  • Ho-nan, Henan, China
    Henan Tumor Hospital
Apr 14, 2022

Breast Cancer Trial in Beijing (Inetetamab, Toripalimab, Albumin-Bound Paclitaxel)

Not yet recruiting
  • Breast Cancer
  • Beijing, China
    Cancer Hospital Chinese Academy Of Medical Sciences
Mar 14, 2022

HNSCC, Oral Cancer, PD-1 Trial in Guangzhou (Perbolizumab+Carboplatin+albumin-bound paclitaxel:4 courses,

Recruiting
  • HNSCC
  • +2 more
  • Perbolizumab+Carboplatin+albumin-bound paclitaxel:4 courses
  • Perbolizumab+Carboplatin+albumin-bound paclitaxel:2 courses
  • Guangzhou, Guangdong, China
    Sun yat-sen memorial hospital
Aug 6, 2023

Triple-negative Breast Cancer Trial in Bengbu (Albumin-Bound Paclitaxel, Apatinib Mesylate, Bevacizumab)

Recruiting
  • Triple-negative Breast Cancer
  • Albumin-Bound Paclitaxel
  • +2 more
  • Bengbu, Anhui, China
    Department of Medical Oncology, First Affiliated Hospital of Ben
Mar 15, 2022

Locally Advanced Breast Carcinoma, Metastatic Breast Carcinoma, Recurrent Breast Carcinoma Trial in United States (Laboratory

Active, not recruiting
Has Results
  • Locally Advanced Breast Carcinoma
  • +7 more
  • Laboratory Biomarker Analysis
  • +2 more
  • Duarte, California
  • +3 more
Jan 31, 2023

Advanced Urothelial Carcinoma Trial in Beijing (anti-PD-L1 antibody, albumin bound paclitaxel)

Active, not recruiting
  • Advanced Urothelial Carcinoma
  • anti-PD-L1 antibody
  • albumin bound paclitaxel
  • Beijing, Beijing, China
    Beijing Tumor Hospital
Jan 20, 2022

Cholangiocarcinoma Trial (Carrilizumab, Albumin-bound paclitaxel, Apatinib)

Not yet recruiting
  • Cholangiocarcinoma
  • (no location specified)
Dec 9, 2022

Soft Tissue Sarcoma Trial in Zhengzhou (Albumin-Bound Paclitaxel, Camrelizumab)

Recruiting
  • Soft Tissue Sarcoma
  • Zhengzhou, Henan, China
    Department of Bone and Soft Tissue, Henan Cancer Hospital
Jan 13, 2022

Solid Tumor, Adult Trial (EOC202, albumin-bound paclitaxel)

Not yet recruiting
  • Solid Tumor, Adult
  • EOC202
  • albumin-bound paclitaxel
  • (no location specified)
Apr 7, 2022

Recurrent Cervical Carcinoma, Persistent Advanced Cervical Carcinoma, Chemo Trial in Beijing (Anti-PD-1 antibody camrelizumab,

Recruiting
  • Recurrent Cervical Carcinoma
  • +5 more
  • Anti-PD-1 antibody camrelizumab
  • Albumin-bound paclitaxel
  • Beijing, Beijing, China
    Lei Li
Mar 12, 2022

Cervical Cancer Trial in Beijing (HLX10+Albumin-Bound Paclitaxel)

Active, not recruiting
  • Cervical Cancer
  • HLX10+Albumin-Bound Paclitaxel
  • Beijing, China
    Cancer Hospital, Chinese Academy of Medical Sciences
May 4, 2022

Second Line Treatment of Gastric Cancer Trial (Camrelizumab, Albumin-Bound Paclitaxel, Irinotecan)

Not yet recruiting
  • Second Line Treatment of Gastric Cancer
  • (no location specified)
Dec 20, 2022

Gastric Cancer Trial in Wuhan (Albumin-bound Paclitaxel plus S-1, Oxaliplatin plus S-1)

Recruiting
  • Gastric Cancer
  • Albumin-bound Paclitaxel plus S-1
  • Oxaliplatin plus S-1
  • Wuhan, Hubei, China
    Tongji hospital of Tongji Medical College, Huazhong University o
Jan 3, 2022